0.94
+1.47%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About IN8bio
From its filings with the US Securities and Exchange Commission
IN8bio is based in New York, New York and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker INAB. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported a net loss of $19.4m. At that date it held total assets of $32.3m and shareholders' equity of $27.6m.
We are a leading clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers ("TCEs") for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess unique properties. They are naturally occurring immune cells that can intrinsically regulate immune responses and have the ability to differentiate between healthy and diseased tissue. These cells serve as a functional bridge between innate and adaptive immunity, contributing to direct tumor-killing as well as immune cell recruitment and activation to drive deeper, more comprehensive immune responses. Multiple studies have demonstrated the robust tumor-killing ability of gamma-delta T cells and superior outcomes in cancer patients with elevated levels of gamma-delta T cells. Recent literature published in 2024 demonstrated that gamma-delta T cell levels are predictive of better survival outcomes even in melanoma patients being treated with checkpoint inhibitors and in leukemia patients being treated with chimeric antigen receptor T cell (“CAR-T”) therapies. The pivotal role of gamma-delta T cells in immune function and activation against diseases such as cancer underscores their therapeutic potential across a wide range of solid and hematologic cancers.
Quoted from its 10-K, filed 12 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 12 Nov 2020
- Employees
- 26
- Website
- in8bio.com ↗
- Head office
- EMPIRE STATE BUILDING, NEW YORK, NY, 10118
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Leadership
Pay as last reported
- Mr. Alan RoemerIndependent Chairman of the Board$175,952
- Mr. William HoPresident, Chief Executive Officer, Director, since 2015$1.5m
- Dr. Lawrence LambCo-Founder, Executive Vice President, Chief Scientific Officer, since 2018$918,754
- Mr. Patrick MccallChief Financial Officer$780,377
- Dr. Kate RochlinChief Operating Officer$934,681
- Mr. Peter BrandtIndependent Director$110,392
- Dr. Corinne EpperlyIndependent Director$104,208
- Ms. Emily FairbairnIndependent Director$83,523
- Dr. Jeremy GraffIndependent Director$107,706
- Ms. Luba GreenwoodIndependent Director$96,346
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- IN8bio's lead product INB-200 is in Phase 1 trials for glioblastoma treatment.
- Gamma-delta T cell technology differentiates IN8bio from competitors in oncology.
- IN8bio's focus on solid and liquid tumors aligns with high unmet medical needs.
Weaknesses
- IN8bio has only 26 employees, limiting operational capacity.
- The company's IPO in November 2020 indicates early-stage financial constraints.
- IN8bio's clinical trials are in early phases, requiring significant future investment.
Opportunities
- INB-400 Phase 2 trial enrollment could accelerate product development.
- Gamma-delta T cell therapies may expand into new cancer types beyond current focus.
- Growing biotech sector in New York City supports IN8bio's research ecosystem.
Threats
- Competition from established biotech firms in the Health Care sector.
- Regulatory hurdles could delay clinical trial approvals for INB-200 and INB-100.
- Financial risks associated with prolonged Phase 1 and Phase 2 trials.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.